TH85268B - A new pyrazole-based HMG Co-A reductase inhibitor - Google Patents
A new pyrazole-based HMG Co-A reductase inhibitorInfo
- Publication number
- TH85268B TH85268B TH501005429A TH0501005429A TH85268B TH 85268 B TH85268 B TH 85268B TH 501005429 A TH501005429 A TH 501005429A TH 0501005429 A TH0501005429 A TH 0501005429A TH 85268 B TH85268 B TH 85268B
- Authority
- TH
- Thailand
- Prior art keywords
- blood
- alkyl
- reductase inhibitor
- mixtures
- normal
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
- 210000004369 Blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010060963 Arterial disease Diseases 0.000 abstract 1
- 229940107161 Cholesterol Drugs 0.000 abstract 1
- 206010012601 Diabetes mellitus Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 206010062060 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010021036 Hyponatraemia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000004316 Oxidoreductases Human genes 0.000 abstract 1
- 108090000854 Oxidoreductases Proteins 0.000 abstract 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 abstract 1
- 200000000007 arterial disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000005516 coenzyme A Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000003389 potentiating Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Abstract
สารประกอบและสารผสมทางเภสัชกรรมใหม่ที่ใช้ประโยชน์เป็นสารที่ทำให้เลือดมี คลอเรสเตอรอลน้อยกว่าปกติและสารที่ทำให้เลือดมีไขมันน้อยกว่าปกติ โดยเฉพาะอย่างยิ่ง, ตัวยับยั้งที่มีศักยภาพของเอนไซม์ 3-ไฮดรอกซี-3-เมทธิลกลูทาริล-โคเอนไซม์ A รีดักเตส ("HMG CoA รีดักเตส") ถูกอธิบาย วิธีการของการใช้สารประกอบและสารผสมดังกล่าวเพื่อทรีทเป้าหมาย, รวมทั้ง มนุษย์, ที่ทรมานจากภาวะที่มีไขมันในเลือดมากกว่าปกติ, ภาวะที่มีคลอเรสเตอรอลในเลือดมากกว่า ปกติ, ภาวะที่มีไตรกลีเซอไรด์ในเลือดมากกว่าปกติ, โรคผนังเส้นเลือดแดงหนา, โรคแอลไซเมอร์, ต่อมลูกหมากโตแบบไม่ร้ายแรง (BPH), โรคเบาหวานและโรคกระดูกพรุนยังถูกอธิบาย Newly utilized pharmaceutical compounds and mixtures are blood-thinning agents. Less cholesterol than normal and substances that make the blood less fat than normal. In particular, potent inhibitors of enzymes 3-hydroxy-3-methyllutaryl-coenzyme A reductase ("HMG CoA Reductase") is described as a method of applying such compounds and mixtures to the tree. Target, including humans, suffering from hyperlipidemia, hypersensitivity, hyponatremia, triglycerides in the blood, thick arterial disease, disease Alzheimer's, benign prostatic hyperplasia (BPH), diabetes and osteoporosis have also been described.
Claims (1)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH85268B true TH85268B (en) | 2007-06-28 |
| TH85268A TH85268A (en) | 2007-06-28 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091620L (en) | Boronic acid and esters as inhibitors of fatty acid amide hydrolases | |
| DE69912581D1 (en) | BIARYL ACETIC ACID DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS | |
| WO2008086226A3 (en) | Factor xa inhibitors | |
| Mertens et al. | Alkynyl–coumarinyl ethers as MAO-B inhibitors | |
| DK1780197T3 (en) | 5-Substituted 2-phenylamino-benzamides as MEK inhibitors | |
| NO20063928L (en) | Substituted quinoline compounds | |
| NO20080865L (en) | Spirochromanone derivatives such as acetyl-coenzyme-A-carboxylase (ACC) inhibitors | |
| MA25809A1 (en) | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | |
| ATE443043T1 (en) | PHENYLCARBOXAMIDE AS A BETA-SECRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S | |
| RS52214B (en) | Pharmaceutical formaulations of hdac inibitors | |
| WO2008086188A3 (en) | Thiophene carboxamides as factor xa inhibitors | |
| NO20091560L (en) | Biaryleterureaforbindelser | |
| WO2006063113A3 (en) | Ureas as factor xa inhibitors | |
| ATE396190T1 (en) | SUBSTITUTED HETEROARYLALKANEOUS ACID AND THEREOF USE AS INHIBITORS OF ALDOSE REDUCTASE | |
| EA200802173A1 (en) | DERIVATIVES OF TERPHENYL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| EP2412707A3 (en) | 3-[2-(3-Amino-2-oxo-2H-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
| ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
| DE60140871D1 (en) | ARYLMETHYLAMINE DERIVATIVES FOR USE AS INHIBITORS OF TRYPTASE | |
| BRPI0518300A2 (en) | 7- (2h-pyrazol-3-yl) -3,5-dihydroxyheptanoic acid derivatives as hmg co-reductase inhibitors for the treatment of lipidemia | |
| ATE466007T1 (en) | 5-SUBSTITUTED INDOLE-2-CARBONIC ACID AMIDE DERIVATIVES | |
| WO2008036316A3 (en) | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| DE602004006118D1 (en) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBOXYL ACID DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER | |
| TH85268B (en) | A new pyrazole-based HMG Co-A reductase inhibitor | |
| DE60034545D1 (en) | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | |
| TH85268A (en) | A new pyrazole-based HMG Co-A reductase inhibitor |